Md Jannatul Islam Polash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Md Jannatul Islam Polash has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Aamal A. Al‐Mutairi
Department of Chemistry, College of Science Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh Kingdom of Saudi Arabia
1 shared publicationAlaa A. Khojah
Department of Pharmaceutical Sciences, College of Pharmacy Umm Al‐Qura University Makkah Saudi Arabia
1 shared publication- Bidduth Kumar Sarkar
Department of Pharmacy, Jahangirnagar University, Savar, Dhaka, Bangladesh
1 shared publication Emad Rashad Sindi
Division of Clinical Biochemistry, Department of Basic Medical Sciences, College of Medicine University of Jeddah Jeddah Saudi Arabia
1 shared publication- Faria Mehjabin Chandni
Department of Pharmacy, Jahangirnagar University, Savar, Dhaka, Bangladesh
1 shared publication - Guilherme Bastos Alves
Department of Biophysics and Pharmacology, Bioscience Center Federal University of Rio Grande do Norte Natal Brazil
1 shared publication
Latest Publications
- Open Access
- 15 November 2026
- Published by Springer Nature in Scientific Reports
Decoding MMP9 allosteric inhibition by Ocimum sanctum bioactives via network pharmacology and molecular dynamics for treating diabetic foot ulcers
- 15 November 2026
- Published by Springer Nature in Scientific Reports
Open AccessDecoding MMP9 allosteric inhibition by Ocimum sanctum bioactives via network pharmacology and molecular dynamics for treating diabetic foot ulcers
- Open Access
- 12 November 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (21) , e70904
Assessment of Annona muricata Phytochemicals as 17β‐HSD1 Inhibitors through Molecular Docking, Dynamics Simulation, DFT, and ADMET Analyses
Breast cancer remains a leading cause of female mortality, largely sustained by local oestrogen production. The enzyme 17β‐hydroxysteroid dehydrogenase type 1 (17β‐HSD1) is an enzyme involved in the oestrogen biosynthesis pathway, particularly in the conversion of estrone to estradiol, and is overexpressed in conditions such as breast cancer. Therefore, it is considered a relevant target for drug development. We evaluated phytocompounds from Annona muricata as prospective 17β‐HSD1 inhibitors through an integrated in silico workflow. Twelve reported constituents (myristic acid, myrcene, palmitic acid, hexanoic acid, pentadecane, methyl 3‐phenylpropionate, butyric acid, linalool, reticuline, phytol, camphene and calamenene) were geometry‐optimised by density‐functional theory, docked against 17β‐HSD1 (PDB 3HB5), and screened for drug‐likeness and ADMET liabilities. The top‐ranked complexes—reticuline (ΔG_pred = −8.4 kcal mol −1 ) and calamenene (−7.7 kcal mol −1 )—scored more favourably than the reference epirubicin (−5.7 kcal mol −1 ) and were subjected to 100 ns molecular‐dynamics simulations. Both ligands remained stably anchored within the catalytic pocket, with root mean square deviation (RMSD) fluctuations below 2.0 Å, yet MM‐PBSA binding free energies (reticuline −27 kJ mol −1 ; calamenene −9 kJ mol −1 ) did not surpass the reference. ADMET profiling predicted acceptable Caco‐2 permeability (0.92–0.94), and only moderate hERG liability, but also signalled potential DILI and carcinogenicity alerts that warrant caution. Reticuline and calamenene fulfilled all of Lipinski's criteria, with the exception of logP in the case of calamenene. Collectively, these findings nominate reticuline and calamenene as promising lead scaffolds for selective intracellular suppression of oestrogen biosynthesis. Experimental validation (enzyme kinetics, cell‐based assays and pharmacokinetic studies) is warranted to confirm their clinical potential in oestrogen‐dependent breast cancer.
- 12 November 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (21) , e70904
Open AccessAssessment of Annona muricata Phytochemicals as 17β‐HSD1 Inhibitors through Molecular Docking, Dynamics Simulation, DFT, and ADMET Analyses
Breast cancer remains a leading cause of female mortality, largely sustained by local oestrogen production. The enzyme 17β‐hydroxysteroid dehydrogenase type 1 (17β‐HSD1) is an enzyme involved in the oestrogen biosynthesis pathway, particularly in the conversion of estrone to estradiol, and is overexpressed in conditions such as breast cancer. Therefore, it is considered a relevant target for drug development. We evaluated phytocompounds from Annona muricata as prospective 17β‐HSD1 inhibitors through an integrated in silico workflow. Twelve reported constituents (myristic acid, myrcene, palmitic acid, hexanoic acid, pentadecane, methyl 3‐phenylpropionate, butyric acid, linalool, reticuline, phytol, camphene and calamenene) were geometry‐optimised by density‐functional theory, docked against 17β‐HSD1 (PDB 3HB5), and screened for drug‐likeness and ADMET liabilities. The top‐ranked complexes—reticuline (ΔG_pred = −8.4 kcal mol −1 ) and calamenene (−7.7 kcal mol −1 )—scored more favourably than the reference epirubicin (−5.7 kcal mol −1 ) and were subjected to 100 ns molecular‐dynamics simulations. Both ligands remained stably anchored within the catalytic pocket, with root mean square deviation (RMSD) fluctuations below 2.0 Å, yet MM‐PBSA binding free energies (reticuline −27 kJ mol −1 ; calamenene −9 kJ mol −1 ) did not surpass the reference. ADMET profiling predicted acceptable Caco‐2 permeability (0.92–0.94), and only moderate hERG liability, but also signalled potential DILI and carcinogenicity alerts that warrant caution. Reticuline and calamenene fulfilled all of Lipinski's criteria, with the exception of logP in the case of calamenene. Collectively, these findings nominate reticuline and calamenene as promising lead scaffolds for selective intracellular suppression of oestrogen biosynthesis. Experimental validation (enzyme kinetics, cell‐based assays and pharmacokinetic studies) is warranted to confirm their clinical potential in oestrogen‐dependent breast cancer.